

ASX Announcement

Recce Pharmaceuticals to Present at World Microbe Forum

Sydney Australia, 18 June 2021: Recce Pharmaceuticals Ltd (**ASX:RCE**) (**FSE:R9Q**) (**Company**), the Company developing New Classes of Synthetic Anti-infectives, has accepted an invitation to present at the World Microbe Forum following confirmation to publish a recent Abstract in the 2021 program.

The presentation will be in the format of an 'iposter' (digital poster) with a live virtual Q&A session by Michele Dilizia, Chief Scientific Officer of Recce Pharmaceuticals. The session presents expanded details on recently announced data supporting the Company's lead synthetic anti-infective compound, RECCE[®] 327, and its novel, multi-layered Mechanism of Action (MoA) at the World Microbe Forum being held virtually on 20-24 June, 2021.

The iposter and abstract will be available on the Company's website, post presentation.

Additional presentation details can be found below:

Title: ***Elucidating the Mechanism of Action of novel polymer-based synthetic anti-infective compound RECCE[®] 327***

Date: Wednesday 23 June 2021

Time: 10:00 am AEST

This announcement has been approved for release by Recce Pharmaceuticals CEO.



ASX: RCE

Head Office: Level 25, 88 Phillip Street, Aurora Place, SYDNEY NSW 2000 **T** +61 (02) 9256 2571

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of New Classes of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens.

Recce's anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE[®] 327, RECCE[®] 435, and RECCE[®] 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.

Patented lead candidate RECCE[®] 327 has been developed for the treatment of blood infections and sepsis derived from *E. coli* and *S. aureus* bacteria – including their superbug forms. Recce's new antibiotic compound, RECCE[®] 435, has been formulated for oral use.

The FDA has awarded RECCE[®] 327 *Qualified Infectious Disease Product* designation under the *Generating Antibiotic Initiatives Now* (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE[®] 327 has been included on The Pew Charitable Trusts *Global New Antibiotics in Development Pipeline* as the only synthetic polymer and sepsis drug candidate in development.

Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials. Recce's anti-infective pipeline seeks to exploit the unique capabilities of RECCE[®] technologies targeting synergistic, unmet medical needs.



Chief Executive Officer

James Graham
Recce Pharmaceuticals Ltd
+61 (02) 9256 2571
james.graham@recce.com.au

Media and Investor Relations (AU)

Andrew Geddes
CityPR
+61 (02) 9267 4511
ageddes@citypublicrelations.com.au

Media and Investor Relations (USA)

Meredith Sosulski, PhD
LifeSci Communications
+1 929 469 3851
msosulski@lifescicomms.com

recce.com.au
ACN 124 849 065